Voices from China at ASCO | Professor Biyun Wang：New First-line Treatment Strategy for mTNBC and Research on the Efficacy Prediction of T-DXd for HER2+ Breast Cancer Brain Metastases Presented

Voices from China at ASCO | Professor Biyun Wang：New First-line Treatment Strategy for mTNBC and Research on the Efficacy Prediction of T-DXd for HER2+ Breast Cancer Brain Metastases Presented

At the 2025 ASCO Annual Meeting, multiple cutting-edge oncology studies were presented. Among them were two studies led by Professor Biyun Wang from Fudan University Shanghai Cancer Center. One was a prospective, single-arm phase II clinical trial (Abstract #1101) evaluating the efficacy and safety of camrelizumab in combination with albumin-bound paclitaxel and cisplatin (the AP regimen) as a first-line treatment for metastatic triple-negative breast cancer (mTNBC). Results showed a median PFS of 11.8 months and median OS of 27.1 months, with manageable toxicity. The second study, an ongoing trial (Abstract #TPS1122), aims to predict treatment response to T-DXd in HER2-positive breast cancer brain metastases using68Ga-FAPI PET-CT to assess tumor metabolic heterogeneity. The trial is actively recruiting patients.This article specifically introduces two studies.
Voices from China at ASCO | Professor Kun Wang Unveils Landmark neoCARHP Study: “Carboplatin-Free” Strategy Redefines Treatment for HER2-Positive Breast Cancer

Voices from China at ASCO | Professor Kun Wang Unveils Landmark neoCARHP Study: “Carboplatin-Free” Strategy Redefines Treatment for HER2-Positive Breast Cancer

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 30 to June 3 in Chicago. At this high-profile event, Professor Kun Wang from Guangdong Provincial People’s Hospital presented the much-anticipated results of the neoCARHP study (Abstract LBA500) during an oral session. The study, which focuses on early-stage HER2-positive breast cancer, offers an innovative head-to-head comparison between a carboplatin-free THP regimen and the traditional carboplatin-containing TCbHP regimen. The findings revealed that the THP regimen was non-inferior to TCbHP in terms of pathological complete response (pCR), with a significantly better toxicity profile. This important discovery not only provides a new therapeutic option for patients with HER2-positive breast cancer but also reflects a patient-centered approach to treatment—marking a shift toward more precise and individualized care. Following the presentation, Oncology Frontier interviewed Professor Wang to discuss the study’s background, significance, and what the future holds for HER2-positive breast cancer treatment.